

## ASX RELEASE

### Johns Hopkins Study Published in Peer-Reviewed Journal

- Study was performed on 500 urine specimens, making it the largest to date
- Published in Acta Cytologica, a leading cytopathology journal
- Expected to result in increased uptake of Sienna's hTERT test for routine clinical use
- Article now available on-line at <https://www.karger.com/Article/FullText/489181>

**Melbourne, Australia, 07 June 2018:** [Sienna Cancer Diagnostics Ltd, \(ASX:SDX\)](#) ("Sienna" or "The Company"), a medical technology company developing and commercialising innovative cancer related tests, is pleased to announce the results of the largest independent study to date using Sienna's IVD test, conducted by Johns Hopkins Hospital, have been published in leading cytopathology journal Acta Cytologica.

The study, authored by researchers from the prestigious Johns Hopkins University School of Medicine in Baltimore, a world-renowned clinical and research hospital, concluded that testing urine samples for hTERT using Sienna's IVD test is a clinically useful adjunct to urine cytology. It found the test may assist in the identification of patients who have an increased risk of bladder cancer.

The availability of the peer-reviewed data is important for driving market adoption. Sienna's CEO Matthew Hoskin commented: "We believe the availability of this peer-reviewed study supporting the clinical utility of our IVD test will provide the extra level of confidence, assurance and validation needed for more laboratories to adopt the test for routine clinical use."

When used as an adjunct to urine cytology, Sienna's IVD had a significantly higher sensitivity to Low-Grade Urothelial Carcinoma (LGUC) compared to urine cytology alone. The test was shown to be most useful where a patient has a low-risk indeterminate urine cytology result, and a negative or absent cystoscopy result. A positive hTERT result may identify patients with an increased risk of bladder cancer who may otherwise not be monitored, while a negative hTERT result is associated with a reduction in the risk of bladder cancer.

"We are excited to see Sienna's IVD test recognised and published on the world-stage. Inclusion in the well-respected, peer-reviewed publication Acta Cytologica, is a fantastic result, and widely read among the pathologists targeted by our distribution partners which is critical to adoption."

To view the study publication, go to <https://www.karger.com/Article/FullText/489181>

ENDS.



**For further information, please contact:**

Matthew Hoskin, CEO  
Sienna Cancer Diagnostics  
mhoskin@siennadiagnostics.com.au  
+61 3 8288 2141

Kyahn Williamson or Lauren Nowak  
WE Buchan  
sienna@we-buchan.com  
+61 3 8866 1200

**About Sienna Cancer Diagnostics**

Sienna Cancer Diagnostics Ltd. is an Australian medical technology company, with operations in the United States, Europe and Australia. Sienna's strengths lie in identifying novel technologies then developing and commercialising them to satisfy an unmet clinical / market need. The Company has demonstrated the utility of its product with the help of its global clinical partners. Sienna's primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009. Telomerase is well recognised for being used by 85% of cancers to enable immortal cell replication.

The FDA listing of Sienna's first IVD in the United States, and CE marking / IVD registration in Europe and Australia, means the assay can be used for clinical diagnostic purposes by pathology laboratories. Clinical pathology laboratories in those regions may purchase the product for use as an in vitro diagnostic test for the presence of hTERT, a component of telomerase.

**Forward Looking Statements**

This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

